Xiangping Qian - Foster City CA, US Gustave Bergnes - Pacifica CA, US Dashyant Dhanak - West Chester PA, US Steven D. Knight - West Chester PA, US Nicholas D. Adams - Royersford PA, US Cynthia A. Parrish - King of Prussia PA, US
Assignee:
Cytokinetics, Inc. - South San Francisco CA SmithKline Beecham Corporation - Philadelphia PA
International Classification:
C07D 471/02 A61K 31/4439
US Classification:
514300, 546121
Abstract:
Provided herein are certain substituted N-phenethylbenzamide of formula V:.
Yanhong Feng - Collegeville PA, US Cynthia A. Parrish - Collegeville PA, US Martha A Sarpong - Collegeville PA, US Domingos J Silva - Collegeville CA, US
Assignee:
SmithKline Beecham Corporation - Philadelphia PA
International Classification:
A61K 31/498
US Classification:
514249, 544353
Abstract:
Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.
Martha Sarpong - Collegeville PA, US Nicholas Adams - Collegeville PA, US Jeffrey Axten - Collegeville PA, US Amita Chaudhari - Collegeville PA, US Dashyant Dhanak - Collegeville PA, US Toshihiro Hamajima - Tsukuba-shi, JP Kenneth Newlander - Collegeville PA, US Cynthia Parrish - Collegeville PA, US Jerry Adams - Collegeville PA, US Domingos Silva - Collegeville PA, US Jun Tang - Durham NC, US
The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.
Naphthyridine, Derivatives As P13 Kinase Inhibitors
Nicholas D. Adams - Collegeville PA, US Joelle L. Burgess - King of Prussia PA, US Amita M. Chaudhari - Collegeville PA, US David Knight - King of Prussia PA, US Cynthia A. Parrish - King of Prussia PA, US
Invented is a method of inhibiting the activity/function of PI3 kinases using naphthyridine derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of naphthyridine derivatives.
Pyridopyrimidine Derivatives As P13 Kinase Inhibitors
Invented is a method of inhibiting the activity/function of PI3 kinases using pyridopyrimidine derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of pyridopyrimidine derivatives.
Amita Chaudhari - Collegeville PA, US Dashyant Dhanak - Collegeville PA, US Carla Ann Donatelli - Collegeville PA, US Thomas H. Faitg - Collegeville PA, US Yanhong Feng - Collegeville PA, US Steven David Knight - Collegeville PA, US Cynthia A. Parrish - Collegeville PA, US Jeffrey M. Ralph - Collegeville PA, US Martha A. Sarpong - Collegeville PA, US Domingos J. Silva - Collegeville PA, US
Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.